Literature DB >> 20425348

Clinical manifestations and treatment of newly diagnosed acute lymphoblastic leukemia in adults.

Heather Landau1, Nicole Lamanna.   

Abstract

Adult acute lymphoblastic leukemia (ALL) is a heterogeneous disease with distinct biologic and prognostic subgroups. The treatment of adults with ALL has evolved largely from the therapy developed for childhood ALL and, despite differences across regimens, can be broadly classified as including induction, consolidation, maintenance, and central nervous system prophylaxis. Although there has been marked improvement in the outcomes for pediatric patients with ALL, the same success has not yet been realized for adult patients. Some of this difference can be attributed to a greater incidence of unfavorable cytogenetic subtypes in adults than in children. In addition, the ability to tolerate intensive regimens likely plays a role. This article reviews the classification, prognostic features, current treatment programs, and new advances as applied to adult patients with newly diagnosed ALL.

Entities:  

Mesh:

Year:  2006        PMID: 20425348     DOI: 10.1007/s11899-996-0005-8

Source DB:  PubMed          Journal:  Curr Hematol Malig Rep        ISSN: 1558-8211            Impact factor:   3.952


  57 in total

1.  Adult acute lymphocytic leukemia: the Eastern Cooperative Oncology Group experience.

Authors:  P A Cassileth; J W Andersen; J M Bennett; H C Hoagland; J J Mazza; M C O'Connell; E Paietta; P Wiernik
Journal:  Leukemia       Date:  1992       Impact factor: 11.528

2.  The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties.

Authors:  J M Chessells; E Hall; H G Prentice; J Durrant; C C Bailey; S M Richards
Journal:  Leukemia       Date:  1998-04       Impact factor: 11.528

3.  Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia.

Authors:  Vanderson Rocha; Myriam Labopin; Guillermo Sanz; William Arcese; Rainer Schwerdtfeger; Alberto Bosi; Niels Jacobsen; Tapani Ruutu; Marcos de Lima; Jürgen Finke; Francesco Frassoni; Eliane Gluckman
Journal:  N Engl J Med       Date:  2004-11-25       Impact factor: 91.245

4.  Duration and intensity of maintenance chemotherapy in acute lymphoblastic leukaemia: overview of 42 trials involving 12 000 randomised children.

Authors: 
Journal:  Lancet       Date:  1996-06-29       Impact factor: 79.321

5.  Cytarabine with high-dose mitoxantrone induces rapid complete remissions in adult acute lymphoblastic leukemia without the use of vincristine or prednisone.

Authors:  M Weiss; P Maslak; E Feldman; E Berman; J Bertino; T Gee; L Megherian; K Seiter; D Scheinberg; D Golde
Journal:  J Clin Oncol       Date:  1996-09       Impact factor: 44.544

Review 6.  Acute lymphoblastic leukemia.

Authors:  Dieter Hoelzer; Nicola Gökbuget; Oliver Ottmann; Ching-Hon Pui; Mary V Relling; Frederick R Appelbaum; Jacques J M van Dongen; Tomasz Szczepański
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2002

7.  Treatment of acute lymphoblastic leukemia in adults: results of the L-10 and L-10M protocols.

Authors:  P Schauer; Z A Arlin; R Mertelsmann; C Cirrincione; A Friedman; T S Gee; M Dowling; S Kempin; D J Straus; B Koziner
Journal:  J Clin Oncol       Date:  1983-08       Impact factor: 44.544

8.  Cytogenetic abnormalities in adult acute lymphoblastic leukemia: correlations with hematologic findings outcome. A Collaborative Study of the Group Français de Cytogénétique Hématologique.

Authors: 
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

Review 9.  Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia.

Authors:  Nicole Lamanna; Mark Weiss
Journal:  Curr Hematol Rep       Date:  2004-01

10.  Long-term follow-up of adults with acute lymphoblastic leukemia in first remission treated with chemotherapy or bone marrow transplantation. The Acute Lymphoblastic Leukemia Working Committee.

Authors:  M J Zhang; D Hoelzer; M M Horowitz; R P Gale; D Messerer; J P Klein; H Löffler; K A Sobocinski; E Thiel; D J Weisdorf
Journal:  Ann Intern Med       Date:  1995-09-15       Impact factor: 25.391

View more
  2 in total

1.  Fluorescence in situ hybridization comparison of the prognostic factors in adult and pediatric acute lymphoblastic leukemia: A retrospective analysis of 282 cases.

Authors:  Pengfei Cao; Yalan Yu; Wei Wang; He Xu; Yuxiang He
Journal:  Exp Ther Med       Date:  2018-10-02       Impact factor: 2.447

Review 2.  Divide and conquer: progress in the molecular stratification of cancer.

Authors:  Patrick Tan
Journal:  Yonsei Med J       Date:  2009-08-19       Impact factor: 2.759

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.